MedTrace Logo

IP-coated Revision Hip Implants

NCT06737809 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2026-01-12

No results posted yet for this study

Summary

The primary aim of the clinical investigation is to demonstrate the efficacy of a silver-based antimicrobial coating on hip implants in the reduction of periprosthetic infections in revision hip arthroplasty due to periprosthetic infection.

Conditions

  • Peri-Prosthetic Joint Infection

Interventions

DEVICE

IP Plasmafit® Revision cup (and stem) system

Revision total hip arthroplasty (THA) due to periprosthetic joint infection

Sponsors & Collaborators

  • Aesculap AG

    lead INDUSTRY

Principal Investigators

  • Sebastian Meller, Dr. · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-25
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06737809 on ClinicalTrials.gov